Endocare Reports Record Revenues of $2.8 Million for First Quarter, Strong Growth in System Sales and Procedures

The Company Cites Continued Increases in Physician Training, National Practice

Group Relationships and Better Outcomes Data



Apr 05, 2001, 01:00 ET from Endocare, Inc.

    IRVINE, Calif., April 5 /PRNewswire/ -- Endocare, Inc. (Nasdaq:   ENDO), a
 developer of innovative temperature-based treatments for prostate cancer and
 prostate obstruction, today reported that accelerating system and disposable
 sales resulted in record revenues of $2.8 million for the first quarter ended
 March 31, 2001, more than doubling the $1.3 million posted in the first
 quarter of 2000.   For the first quarter of 2001, system sales increased by
 approximately 160 percent over those posted in the 2000 first quarter, while
 overall procedures increased by approximately 60 percent in the first quarter
 of this year over last.  The Company expects to announce its full results for
 the first quarter and conduct a results conference call the second week in
 May.
     According to Endocare Chairman and Chief Executive Officer, Paul W. Mikus,
 "The Urology community is embracing Cryoablation at an accelerating rate.
 Historical data combined with excellent clinical outcomes being achieved today
 and increased levels of reimbursement are driving greater demand and, we
 believe, will eventually make cryoablation the first choice for minimally
 invasive treatment of prostate cancer.
     "In addition," Mikus said, "those patients whose cancer has recurred
 following radiation therapy will be eligible for full Medicare reimbursement
 starting later this year.  We believe that the addition of this patient
 population will accelerate the volume of procedures in the second half of the
 year."
 
     About Endocare
     Endocare, Inc. -- www.endocare.com -- is a vertically-integrated medical
 device company that develops, manufactures and markets cryosurgical and stent
 technologies for applications in oncology and urology.  The Company has
 initially concentrated on developing devices for the treatment of the two most
 common diseases of the prostate, prostate cancer and benign prostate
 hyperplasia.  The Company is also developing cryosurgical technologies for
 treating tumors in other organs, including the kidney, breast and liver.
 
     This release contains forward-looking statements.  These statements are
 subject to risk and uncertainties including, but not limited to, those
 discussed in the Company's most recent Annual Report on Form 10-K, Quarterly
 Report on Form 10-Q and other filings with the Securities and Exchange
 Commission.  Such risk factors include, but are not limited to, limited
 operating history of the Company with a history of losses; fluctuations in the
 Company's order levels; uncertainty regarding market acceptance of the
 Company's new products; uncertainty of product development and the associated
 risks related to clinical trials; the rapid pace of technological change in
 the Company's industry; the Company's limited sales, marketing and
 manufacturing experience; the ability to secure and protect intellectual
 property rights relating to the Company's technology and the ability to
 convince health care professionals and third party payers of the medical and
 economic benefits of the Company's products.  The actual results that the
 Company achieves may differ materially from any forward looking statements due
 to such risks and uncertainties.  We undertake no obligation to revise or
 update publicly any forward-looking statements for any reason.
 
     For further information, please contact: Investors, Matt Clawson,
 matt@allencaron.com, or Media, Len Hall, Len@allencaron.com, both of Allen &
 Caron, Inc., 949-474-4300, for Endocare, Inc.; or Paul Mikus, President and
 CEO, or William Hughes, Senior Vice President and CFO, of Endocare, Inc.,
 949-595-4770.
 
 

SOURCE Endocare, Inc.
    IRVINE, Calif., April 5 /PRNewswire/ -- Endocare, Inc. (Nasdaq:   ENDO), a
 developer of innovative temperature-based treatments for prostate cancer and
 prostate obstruction, today reported that accelerating system and disposable
 sales resulted in record revenues of $2.8 million for the first quarter ended
 March 31, 2001, more than doubling the $1.3 million posted in the first
 quarter of 2000.   For the first quarter of 2001, system sales increased by
 approximately 160 percent over those posted in the 2000 first quarter, while
 overall procedures increased by approximately 60 percent in the first quarter
 of this year over last.  The Company expects to announce its full results for
 the first quarter and conduct a results conference call the second week in
 May.
     According to Endocare Chairman and Chief Executive Officer, Paul W. Mikus,
 "The Urology community is embracing Cryoablation at an accelerating rate.
 Historical data combined with excellent clinical outcomes being achieved today
 and increased levels of reimbursement are driving greater demand and, we
 believe, will eventually make cryoablation the first choice for minimally
 invasive treatment of prostate cancer.
     "In addition," Mikus said, "those patients whose cancer has recurred
 following radiation therapy will be eligible for full Medicare reimbursement
 starting later this year.  We believe that the addition of this patient
 population will accelerate the volume of procedures in the second half of the
 year."
 
     About Endocare
     Endocare, Inc. -- www.endocare.com -- is a vertically-integrated medical
 device company that develops, manufactures and markets cryosurgical and stent
 technologies for applications in oncology and urology.  The Company has
 initially concentrated on developing devices for the treatment of the two most
 common diseases of the prostate, prostate cancer and benign prostate
 hyperplasia.  The Company is also developing cryosurgical technologies for
 treating tumors in other organs, including the kidney, breast and liver.
 
     This release contains forward-looking statements.  These statements are
 subject to risk and uncertainties including, but not limited to, those
 discussed in the Company's most recent Annual Report on Form 10-K, Quarterly
 Report on Form 10-Q and other filings with the Securities and Exchange
 Commission.  Such risk factors include, but are not limited to, limited
 operating history of the Company with a history of losses; fluctuations in the
 Company's order levels; uncertainty regarding market acceptance of the
 Company's new products; uncertainty of product development and the associated
 risks related to clinical trials; the rapid pace of technological change in
 the Company's industry; the Company's limited sales, marketing and
 manufacturing experience; the ability to secure and protect intellectual
 property rights relating to the Company's technology and the ability to
 convince health care professionals and third party payers of the medical and
 economic benefits of the Company's products.  The actual results that the
 Company achieves may differ materially from any forward looking statements due
 to such risks and uncertainties.  We undertake no obligation to revise or
 update publicly any forward-looking statements for any reason.
 
     For further information, please contact: Investors, Matt Clawson,
 matt@allencaron.com, or Media, Len Hall, Len@allencaron.com, both of Allen &
 Caron, Inc., 949-474-4300, for Endocare, Inc.; or Paul Mikus, President and
 CEO, or William Hughes, Senior Vice President and CFO, of Endocare, Inc.,
 949-595-4770.
 
 SOURCE  Endocare, Inc.